KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Halozyme Therapeutics (HALO) over the last 16 years, with Q4 2025 value amounting to $33.8 million.

  • Halozyme Therapeutics' Change in Accured Expenses fell 3255.29% to $33.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $6.2 million, marking a year-over-year decrease of 8678.31%. This contributed to the annual value of $6.2 million for FY2025, which is 8678.31% down from last year.
  • Halozyme Therapeutics' Change in Accured Expenses amounted to $33.8 million in Q4 2025, which was down 3255.29% from -$7.2 million recorded in Q3 2025.
  • Halozyme Therapeutics' Change in Accured Expenses' 5-year high stood at $50.2 million during Q4 2024, with a 5-year trough of -$29.7 million in Q2 2025.
  • Its 5-year average for Change in Accured Expenses is $3.3 million, with a median of -$812500.0 in 2022.
  • In the last 5 years, Halozyme Therapeutics' Change in Accured Expenses crashed by 300766.87% in 2023 and then surged by 62944.4% in 2024.
  • Over the past 5 years, Halozyme Therapeutics' Change in Accured Expenses (Quarter) stood at $3.5 million in 2021, then tumbled by 90.61% to $326000.0 in 2022, then crashed by 3007.67% to -$9.5 million in 2023, then skyrocketed by 629.44% to $50.2 million in 2024, then crashed by 32.55% to $33.8 million in 2025.
  • Its Change in Accured Expenses stands at $33.8 million for Q4 2025, versus -$7.2 million for Q3 2025 and -$29.7 million for Q2 2025.